Cargando…
Prolonged response of recurrent IDH-wild-type glioblastoma to laser interstitial thermal therapy with pembrolizumab
Despite the improved understanding of the molecular and genetic heterogeneity of glioblastoma, there is still an unmet need for better therapeutics, as treatment approaches have remained unchanged in recent years. Research into the role of the immune microenvironment has generated enthusiasm for tes...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Medicine Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988254/ https://www.ncbi.nlm.nih.gov/pubmed/35043686 http://dx.doi.org/10.2217/cns-2021-0013 |
_version_ | 1784682921451323392 |
---|---|
author | Hwang, Helen Huang, Jiayi Khaddour, Karam Butt, Omar H Ansstas, George Chen, Jie Katumba, Ruth GN Kim, Albert H Leuthardt, Eric C Campian, Jian L |
author_facet | Hwang, Helen Huang, Jiayi Khaddour, Karam Butt, Omar H Ansstas, George Chen, Jie Katumba, Ruth GN Kim, Albert H Leuthardt, Eric C Campian, Jian L |
author_sort | Hwang, Helen |
collection | PubMed |
description | Despite the improved understanding of the molecular and genetic heterogeneity of glioblastoma, there is still an unmet need for better therapeutics, as treatment approaches have remained unchanged in recent years. Research into the role of the immune microenvironment has generated enthusiasm for testing immunotherapy (specifically, immune checkpoint inhibitors). However, to date, trials of immunotherapy in glioblastoma have not demonstrated a survival advantage. Combination approaches aimed at optimally inducing response to immune checkpoint inhibitors with radiotherapy are currently being investigated. Herein, the authors describe their experience of the potential benefit and clinical outcomes of using combination pembrolizumab (an immune checkpoint inhibitor) and laser interstitial thermal therapy in a case series of patients with recurrent IDH-wild-type glioblastoma. |
format | Online Article Text |
id | pubmed-8988254 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Future Medicine Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-89882542022-04-11 Prolonged response of recurrent IDH-wild-type glioblastoma to laser interstitial thermal therapy with pembrolizumab Hwang, Helen Huang, Jiayi Khaddour, Karam Butt, Omar H Ansstas, George Chen, Jie Katumba, Ruth GN Kim, Albert H Leuthardt, Eric C Campian, Jian L CNS Oncol Case Series Despite the improved understanding of the molecular and genetic heterogeneity of glioblastoma, there is still an unmet need for better therapeutics, as treatment approaches have remained unchanged in recent years. Research into the role of the immune microenvironment has generated enthusiasm for testing immunotherapy (specifically, immune checkpoint inhibitors). However, to date, trials of immunotherapy in glioblastoma have not demonstrated a survival advantage. Combination approaches aimed at optimally inducing response to immune checkpoint inhibitors with radiotherapy are currently being investigated. Herein, the authors describe their experience of the potential benefit and clinical outcomes of using combination pembrolizumab (an immune checkpoint inhibitor) and laser interstitial thermal therapy in a case series of patients with recurrent IDH-wild-type glioblastoma. Future Medicine Ltd 2022-01-19 /pmc/articles/PMC8988254/ /pubmed/35043686 http://dx.doi.org/10.2217/cns-2021-0013 Text en © 2022 Jian L Campian https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | Case Series Hwang, Helen Huang, Jiayi Khaddour, Karam Butt, Omar H Ansstas, George Chen, Jie Katumba, Ruth GN Kim, Albert H Leuthardt, Eric C Campian, Jian L Prolonged response of recurrent IDH-wild-type glioblastoma to laser interstitial thermal therapy with pembrolizumab |
title | Prolonged response of recurrent IDH-wild-type glioblastoma to laser interstitial thermal therapy with pembrolizumab |
title_full | Prolonged response of recurrent IDH-wild-type glioblastoma to laser interstitial thermal therapy with pembrolizumab |
title_fullStr | Prolonged response of recurrent IDH-wild-type glioblastoma to laser interstitial thermal therapy with pembrolizumab |
title_full_unstemmed | Prolonged response of recurrent IDH-wild-type glioblastoma to laser interstitial thermal therapy with pembrolizumab |
title_short | Prolonged response of recurrent IDH-wild-type glioblastoma to laser interstitial thermal therapy with pembrolizumab |
title_sort | prolonged response of recurrent idh-wild-type glioblastoma to laser interstitial thermal therapy with pembrolizumab |
topic | Case Series |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988254/ https://www.ncbi.nlm.nih.gov/pubmed/35043686 http://dx.doi.org/10.2217/cns-2021-0013 |
work_keys_str_mv | AT hwanghelen prolongedresponseofrecurrentidhwildtypeglioblastomatolaserinterstitialthermaltherapywithpembrolizumab AT huangjiayi prolongedresponseofrecurrentidhwildtypeglioblastomatolaserinterstitialthermaltherapywithpembrolizumab AT khaddourkaram prolongedresponseofrecurrentidhwildtypeglioblastomatolaserinterstitialthermaltherapywithpembrolizumab AT buttomarh prolongedresponseofrecurrentidhwildtypeglioblastomatolaserinterstitialthermaltherapywithpembrolizumab AT ansstasgeorge prolongedresponseofrecurrentidhwildtypeglioblastomatolaserinterstitialthermaltherapywithpembrolizumab AT chenjie prolongedresponseofrecurrentidhwildtypeglioblastomatolaserinterstitialthermaltherapywithpembrolizumab AT katumbaruthgn prolongedresponseofrecurrentidhwildtypeglioblastomatolaserinterstitialthermaltherapywithpembrolizumab AT kimalberth prolongedresponseofrecurrentidhwildtypeglioblastomatolaserinterstitialthermaltherapywithpembrolizumab AT leuthardtericc prolongedresponseofrecurrentidhwildtypeglioblastomatolaserinterstitialthermaltherapywithpembrolizumab AT campianjianl prolongedresponseofrecurrentidhwildtypeglioblastomatolaserinterstitialthermaltherapywithpembrolizumab |